Pay in 4 interest-free payments of $6.59 Learn more
Ships within 48 hours · Estimated delivery Sep 7 - Sep 12
Abstract Peptide agonists of the glucagon-like peptide-1 receptor (GLP-1R) have revolutionized diabetes therapy, but their use has been limited by the requirement for injection
This is not becoming one large obesity market
Cardiovascular risk reduction in diabetic patients is the fastest-growing end-use segment for GLP-1 drugs, capturing 20% of market value
If they include a GLP-1 medication, this should include: appropriate dosing gradual titration monitoring of side effects maintenance planning to help you align treatment with your individual health goals
US$ 21.04
US$ 19.99
US$ 29.24
US$ 27.65
US$ 26.65
US$ 22.81
US$ 25.20
